NEUP
Income statement / Annual
Last year (2025), Neuphoria Therapeutics Inc.'s total revenue was $23.95 M,
and the percentage change from the previous year is not available.
In 2025, Neuphoria Therapeutics Inc.'s net income was -$565.77 K.
See Neuphoria Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$23.95 M |
$0.00 |
$0.00 |
$277.89 K |
$0.00 |
$45.13 K |
$717.53 K |
$3.95 M |
$18.17 M |
$7.79 M |
| Cost of Revenue |
$1.01 M
|
$992.56 K
|
$671.42 K
|
$0.00
|
$1.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$22.94 M
|
-$992.56 K
|
-$671.42 K
|
$0.00
|
-$1.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.96
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$13.78 M
|
$14.10 M
|
$13.23 M
|
$16.86 M
|
$5.73 M
|
$5.64 M
|
$12.41 M
|
$26.57 M
|
$23.85 M
|
$24.16 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.88 M
|
$11.69 M
|
$8.35 M
|
$10.84 M
|
$5.53 M
|
$3.72 M
|
$6.94 M
|
$6.11 M
|
$6.44 M
|
$10.05 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$24.67 M
|
$25.79 M
|
$21.58 M
|
$27.71 M
|
$11.26 M
|
$9.36 M
|
$19.34 M
|
$32.68 M
|
$30.30 M
|
$34.21 M
|
| Cost And Expenses |
$25.68 M
|
$26.79 M
|
$22.26 M
|
$28.88 M
|
$12.95 M
|
$11.72 M
|
$21.09 M
|
$34.43 M
|
$32.01 M
|
$36.10 M
|
| Interest Income |
$166.50 K
|
$220.10 K
|
$323.16 K
|
$6.79 K
|
$4.29 K
|
$39.13 K
|
$197.95 K
|
$422.32 K
|
$925.02 K
|
$915.95 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$18.49 K
|
$1.08 M
|
$1.24 M
|
$1.66 M
|
$1.51 M
|
$1.51 M
|
$1.41 M
|
| Depreciation & Amortization |
$1.01 M
|
$992.56 K
|
$671.42 K
|
$1.17 M
|
$1.69 M
|
$2.36 M
|
$1.75 M
|
$1.76 M
|
$1.72 M
|
$1.89 M
|
| EBITDA |
-$268.03 K |
-$22.33 M |
-$21.54 M |
-$28.03 M |
-$6.63 M |
-$4.53 M |
-$13.05 M |
-$30.96 M |
-$9.43 M |
-$22.57 M |
| EBITDA Ratio |
-0.01
|
0
|
0
|
-100.86
|
0
|
-100.35
|
-18.19
|
-7.84
|
-0.52
|
-2.9
|
| Operating Income Ratio |
-0.07
|
0
|
0
|
-102.92
|
0
|
-258.66
|
-28.39
|
-7.72
|
-0.76
|
-3.63
|
| Total Other Income/Expenses Net |
$445.56 K
|
$3.46 M
|
$39.87 K
|
-$642.61 K
|
$3.19 M
|
$3.00 M
|
$2.95 M
|
-$4.05 M
|
$918.89 K
|
$2.16 M
|
| Income Before Tax |
-$1.28 M
|
-$23.32 M
|
-$22.22 M
|
-$29.24 M
|
-$9.76 M
|
-$8.68 M
|
-$17.42 M
|
-$34.53 M
|
-$12.93 M
|
-$26.16 M
|
| Income Before Tax Ratio |
-0.05
|
0
|
0
|
-105.23
|
0
|
-192.29
|
-24.28
|
-8.74
|
-0.71
|
-3.36
|
| Income Tax Expense |
-$716.90 K
|
-$130.73 K
|
-$568.89 K
|
-$6.31 M
|
-$1.11 M
|
-$3.05 M
|
-$6.78 M
|
-$8.13 M
|
-$6.28 M
|
-$9.98 M
|
| Net Income |
-$565.77 K
|
-$23.19 M
|
-$21.65 M
|
-$22.94 M
|
-$8.65 M
|
-$6.89 M
|
-$10.60 M
|
-$26.40 M
|
-$6.65 M
|
-$16.18 M
|
| Net Income Ratio |
-0.02
|
0
|
0
|
-82.54
|
0
|
-152.56
|
-14.77
|
-6.68
|
-0.37
|
-2.08
|
| EPS |
-0.23 |
-0.1 |
-0.17 |
-0.13 |
-0.1 |
-0.11 |
-0.16 |
-0.46 |
-0.13 |
-0.33 |
| EPS Diluted |
-0.23 |
-0.1 |
-0.17 |
-0.13 |
-0.1 |
-0.11 |
-0.16 |
-0.46 |
-0.13 |
-0.33 |
| Weighted Average Shares Out |
$1.62 M
|
$149.80 M
|
$122.39 M
|
$112.78 M
|
$65.00 M
|
$45.41 M
|
$43.44 M
|
$40.19 M
|
$40.11 M
|
$38.10 M
|
| Weighted Average Shares Out Diluted |
$1.62 M
|
$149.80 M
|
$122.39 M
|
$112.78 M
|
$65.00 M
|
$45.41 M
|
$43.44 M
|
$40.19 M
|
$40.11 M
|
$38.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
